Acurx Pharmaceuticals, INC

Acurx Pharmaceuticals has entered into a definitive agreement for a registered direct offering and concurrent private placement to raise approximately $2.5 million in gross proceeds.

Acurx Pharmaceuticals, Inc. stockholders approved an amendment to increase authorized common stock from 200 million to 250 million shares.

Acurx Pharmaceuticals' stockholders approved the issuance of shares underlying Series G-2 warrants and an increase in authorized common stock from 200 million to 250 million shares.

Acurx Pharmaceuticals, a late-stage biopharmaceutical company, announced a 1-for-20 reverse stock split to increase its share price and regain compliance with Nasdaq's minimum bid price requirement.

Acurx Pharmaceuticals, Inc. shareholders approved all six proposals at its Annual Meeting, including a reverse stock split, the issuance of shares for warrant exercises and an equity line of credit, and an increase in the 2021 Equity Incentive Plan.

Acurx Pharmaceuticals, Inc. has entered into a warrant inducement agreement, generating approximately $2.3 million in net proceeds by inducing the exercise of existing warrants at a reduced price and issuing new, highly dilutive warrants.

Acurx Pharmaceuticals reports Q1 2026 results, focusing on ibezapolstat development and ongoing financing efforts.

Acurx Pharmaceuticals reported significantly reduced net losses and increased cash reserves for the nine months ended September 30, 2025, while regaining Nasdaq compliance.

Acurx Pharmaceuticals reported a significant reduction in net loss and increased cash, but faces substantial doubt about its ability to continue as a going concern and Nasdaq listing compliance issues.

Acurx Pharmaceuticals announces its Q1 2025 financial results, highlighting a net loss of $2.1 million and a new $12 million purchase agreement with Lincoln Park Capital.

Acurx Pharmaceuticals reported a net loss of $2.8 million for the third quarter of 2024, while continuing to advance its lead antibiotic candidate, ibezapolstat.

Acurx Pharmaceuticals reported a net loss of $4.1 million for the second quarter of 2024, while continuing to advance its lead antibiotic candidate, ibezapolstat.

Acurx Pharmaceuticals' 2024 10-K filing details the company's financial status and the advancement of its lead drug candidate, ibezapolstat, through clinical trials for Clostridioides difficile infection (CDI).

Acurx Pharmaceuticals' 10-K filing outlines the company's common and preferred stock structure, warrant details, and key corporate governance provisions.

Director Carl Sailer was granted 2,150 stock options as part of the Acurx Pharmaceuticals director compensation policy.

Director Jack H. Dean was granted 2,150 stock options as part of the Acurx Pharmaceuticals director compensation policy.

Acurx Pharmaceuticals director James J. Donohue was granted 2,150 stock options as part of the company's director compensation policy.

Director Thomas L. Harrison was granted 2,150 stock options as part of the company's director compensation policy.

Director Joseph C. Scodari was granted 2,150 stock options as part of the Acurx Pharmaceuticals director compensation policy.

Director Robert J. DeLuccia was granted 37,100 stock options in Acurx Pharmaceuticals, Inc. as part of a compensation plan.

Acurx Pharmaceuticals, Inc. is seeking shareholder approval for the issuance of shares related to Series G-2 warrants and an increase in its authorized common stock ahead of its September 16, 2025 Special Meeting.

Acurx Pharmaceuticals, Inc. is seeking stockholder approval for a significant common stock issuance related to a recent financing and an increase in authorized shares to support future corporate actions.

Acurx Pharmaceuticals, Inc. is seeking shareholder approval for a reverse stock split, significant share issuances for capital raising, and an increase in its equity incentive plan ahead of its 2025 Annual Meeting.

Acurx Pharmaceuticals, Inc. is calling its 2025 Annual Meeting to approve a reverse stock split to regain Nasdaq compliance, authorize significant share issuances for capital, and expand its equity incentive plan.

Acurx Pharmaceuticals announces its 2024 Annual Meeting of Stockholders to be held virtually on June 17, 2024, with proposals including the election of directors and ratification of independent auditors.

Acurx Pharmaceuticals announces its 2024 annual meeting of stockholders to be held virtually on June 17, 2024, focusing on director elections and auditor ratification.

Acurx Pharmaceuticals, Inc. has filed a Form S-1 registration statement to allow Lincoln Park Capital Fund, LLC to resell up to 1,300,000 shares of common stock.

Acurx Pharmaceuticals, Inc. has filed a Form S-1 with the SEC to register for resale up to 1,650,170 shares of its common stock issuable upon exercise of Series H warrants.

Acurx Pharmaceuticals files an S-1 registration statement for the resale of up to 750,000 common shares by Lincoln Park Capital Fund, LLC, potentially raising up to $7.6 million for the company.

Acurx Pharmaceuticals filed an S-1 registration statement for the resale of up to 585,000 common shares by Lincoln Park Capital Fund, LLC, enabling the company to potentially raise an additional $9.0 million.

A biopharmaceutical company is registering a significant resale of common stock by existing holders, while grappling with Nasdaq non-compliance issues and a 'going concern' audit opinion, signaling substantial financial challenges.

Acurx Pharmaceuticals has filed a registration statement for the resale of up to 10,899,258 shares of its common stock by Lincoln Park Capital Fund, LLC.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, disclosing a 4.99% beneficial ownership stake in Acurx Pharmaceuticals, Inc.

Armistice Capital and Steven Boyd have disclosed a passive 8.7% beneficial ownership stake in Acurx Pharmaceuticals, Inc. common stock.